Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals.
It operates through United States, International, and Operating Cost segments.
The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS.
The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors.
It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases.
Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | -0.06 Increased by +95.45% | -0.04 Decreased by -50.00% |
| May 14, 24 | -0.12 Increased by +83.10% | -0.06 Decreased by -100.00% |
| Mar 7, 24 | -0.07 Increased by +87.04% | 0.18 Decreased by -138.89% |
| Oct 26, 23 | -0.06 Increased by +92.00% | -0.06 |
| Aug 10, 23 | -1.32 Decreased by -193.33% | 0.02 Decreased by -6.70 K% |
| May 15, 23 | -0.71 Increased by +16.47% | -0.51 Decreased by -39.22% |
| Mar 31, 23 | -0.54 Increased by +8.47% | -0.33 Decreased by -63.64% |
| Nov 14, 22 | -0.75 Decreased by -25.00% | -0.40 Decreased by -87.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 27.00 M Increased by +53.95% | -3.31 M Increased by +66.99% | Decreased by -12.26% Increased by +78.56% |
| Mar 31, 24 | 23.01 M Increased by +69.87% | -6.25 M Increased by +24.70% | Decreased by -27.17% Increased by +55.67% |
| Dec 31, 23 | 26.31 M Increased by +87.51% | -3.78 M Decreased by -0.03% | Decreased by -14.37% Increased by +46.66% |
| Sep 30, 23 | 23.36 M Increased by +71.82% | -1.35 M Increased by +74.24% | Decreased by -5.80% Increased by +85.01% |
| Jun 30, 23 | 17.54 M Increased by +20.09% | -10.03 M Decreased by -221.96% | Decreased by -57.18% Decreased by -168.10% |
| Mar 31, 23 | 13.55 M Increased by +13.85% | -8.30 M Decreased by -6.93% | Decreased by -61.28% Increased by +6.08% |
| Dec 31, 22 | 14.03 M Increased by +0.50% | -3.78 M Increased by +7.94% | Decreased by -26.94% Increased by +8.40% |
| Sep 30, 22 | 13.60 M Increased by +11.89% | -5.26 M Decreased by -25.68% | Decreased by -38.66% Decreased by -12.32% |